首页 > 最新文献

Chinese Journal of Clinical Hepatology最新文献

英文 中文
IDDF2021-ABS-0008 Is fatty liver associated with depression? A meta-analysis and systematic review on prevalence, risk factors and outcomes of depression and non-alcoholic fatty liver disease 脂肪肝与抑郁症相关吗?抑郁症和非酒精性脂肪肝患病率、危险因素及预后的meta分析和系统综述
Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.61
C. Ng, J. Xiao, Lincoln Kai En Lim, D. Tan, W. Lim, Cyrus S. H. Ho, E. Tan, A. Sanyal, M. Muthiah
IDDF2021-ABS-0008 Figure 1 Abstracts A64 Gut 2021;70(Suppl 2):A1–A150 on S etem er 1, 2021 by gest. P rocted by coright. http/gut.bm jcom / G t: frst pulished as 10.113utjnl-2021-ID D F 61 on 2 S etem er 221. D ow nladed fom aimed to assess the association between depression and NAFLD. Methods A search of the literature was conducted on Medline and Embase databases to identify articles relating to NAFLD and depression. A meta-analysis of proportions was conducted using the generalized linear mix model with Copper Pearson intervals to stabilize the variance. Risk factors were analyzed using the odds ratios and mean difference for dichotomous and continuous variables respectively. To compare between the rate of depression between NAFLD (non-alcholic fatty liver disease) and NASH (nonalcoholic steatohepatitis), the relative risks (RR) were calculated using the depression in NASH vs NAFLD as the ratio of the pooled proportion and confidence interval by the Katz-logarithmic method. Results Of 1315 unique abstracts identified, 10 articles involving 2,041,752 NAFLD patients were included (IDDF2021ABS-0008 Figure 1. Overall Prevalence of Depression in NAFLD). In a pooled analysis of studies, there was a significant relationship between the diagnosis of depression and NAFLD (OR: 1.29, CI: 1.02 1.64, p=0.03). The overall pooled prevalence of depression in NAFLD was14.39% (CI: 8.89% 22.45%). The prevalence of depression in nonalcoholic steatohepatitis (NASH) is 40.68% (CI: 25.11% 58.37%), significantly higher than that in NAFLD at 14.39% (CI: 8.89% 22.45%). Compared to NAFLD, patients with NASH had a significantly higher risk of depression (RR: 2.83, CI: 2.41 3.32, p <0.001). Diabetes, BMI, female sex, history of smoking and history of lung disease were significant risk factors associated with depression in NAFLD patients and depression in NAFLD patients was an independent predictor of all-cause 1-year mortality. Conclusions To our knowledge, this is the first meta-analysis to describe a positive association between NAFLD and depression with an increasing rate of depression in NASH compared to NAFLD (IDDF2021-ABS-0008 Figure 2. Graphical Depiction of the Overall Results). However, more studies are required to observe the impact of depression and clinical outcomes in NAFLD. IDDF2021-ABS-0010 A META-ANALYSIS AND METAREGRESSION BETWEEN LIVER RESECTION AND LIVER TRANSPLANT WITHIN MILIAN CRITERIA Cheng Han Ng*, Jin Hean Koh, Yuki Ong, Wen Hui Lim, Darren Jun Hao Tan, Mark Muthiah, Nicholas Syn, Brian Goh, Daniel Huang. Yong Loo Lin School of Medicine, Singapore; Singapore General Hospital, Singapore 10.1136/gutjnl-2021-IDDF.62 Background Hepatocellular carcinoma (HCC) is the dominant form of primary liver cancer and a leading cause of cancer globally. Liver transplantation (LT) confers excellent long-term survival outcomes, but its effectiveness is hampered by the dire shortage of liver allografts. Liver resection (LR) is a promising alternative due to favorable
摘要A64 Gut 2021;70(补品2):A1-A150在S etem er 1上,2021按最大。P由赖特保护。http /直觉。jj.com / gt:首次发表为10.113utjnl-2021-ID D F 61, 2月1日第221期。本研究旨在评估抑郁症与NAFLD之间的关系。方法在Medline和Embase数据库中检索与NAFLD和抑郁症相关的文献。采用广义线性混合模型铜Pearson区间进行比例的元分析以稳定方差。危险因素分别采用二分变量和连续变量的比值比和均数差进行分析。为了比较NAFLD(非酒精性脂肪性肝病)和NASH(非酒精性脂肪性肝炎)之间的抑郁率,使用NASH与NAFLD的抑郁作为合并比例和置信区间的比值,通过katz -对数方法计算相对风险(RR)。结果在鉴定的1315篇独特摘要中,纳入了10篇文章,涉及2,041,752例NAFLD患者(IDDF2021ABS-0008)。NAFLD患者抑郁的总体患病率。在一项研究的汇总分析中,抑郁症的诊断与NAFLD之间存在显著关系(OR: 1.29, CI: 1.02 - 1.64, p=0.03)。NAFLD患者抑郁的总总患病率为14.39% (CI: 8.89% - 22.45%)。非酒精性脂肪性肝炎(NASH)患者抑郁患病率为40.68% (CI: 25.11% ~ 58.37%),显著高于NAFLD患者的14.39% (CI: 8.89% ~ 22.45%)。与NAFLD相比,NASH患者发生抑郁的风险明显更高(RR: 2.83, CI: 2.41 3.32, p <0.001)。糖尿病、BMI、女性、吸烟史和肺部疾病史是NAFLD患者抑郁相关的重要危险因素,NAFLD患者抑郁是1年全因死亡率的独立预测因子。据我们所知,这是第一个描述NAFLD和抑郁症之间正相关的荟萃分析,与NAFLD相比,NASH中抑郁症的发生率增加(IDDF2021-ABS-0008图2)。整体结果的图形描述)。然而,需要更多的研究来观察抑郁症对NAFLD的影响和临床结果。肝切除和肝移植在MILIAN标准下的meta分析和meta回归分析吴成汉*,Koh Jin Hean, Ong Yuki, Lim Wen Hui, Darren Jun Hao Tan, Mark Muthiah, Nicholas Syn, Brian Goh, Daniel Huang。新加坡永禄林医学院;新加坡总医院,新加坡10.1136/gutjnl-2021-IDDF.62肝细胞癌(HCC)是原发性肝癌的主要形式,也是全球癌症的主要原因。肝移植(LT)提供了良好的长期生存结果,但其有效性受到同种异体肝脏移植严重短缺的阻碍。肝切除(LR)是一种很有希望的替代方法,因为它具有良好的长期预后。我们试图进行一项荟萃分析,以比较米兰标准下肝细胞癌肝移植和肝切除的生存结果。方法检索Medline和Embase数据库,比较MC内HCC患者肝移植和肝移植后的生存数据。使用DerSimonian和Laird随机效应模型进行风险比(HR)荟萃分析,比较肝移植和肝移植患者的总生存期(OS)和无病生存期(DFS)。肠道2021;70(补充2):A1-A150 A65在S etem er 1上,2021按最大。P由赖特保护。http /直觉。jj.com / gt:首次发表为10.113utjnl-2021-ID D F 61, 2月1日第221期。我们从
{"title":"IDDF2021-ABS-0008 Is fatty liver associated with depression? A meta-analysis and systematic review on prevalence, risk factors and outcomes of depression and non-alcoholic fatty liver disease","authors":"C. Ng, J. Xiao, Lincoln Kai En Lim, D. Tan, W. Lim, Cyrus S. H. Ho, E. Tan, A. Sanyal, M. Muthiah","doi":"10.1136/gutjnl-2021-iddf.61","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.61","url":null,"abstract":"IDDF2021-ABS-0008 Figure 1 Abstracts A64 Gut 2021;70(Suppl 2):A1–A150 on S etem er 1, 2021 by gest. P rocted by coright. http/gut.bm jcom / G t: frst pulished as 10.113utjnl-2021-ID D F 61 on 2 S etem er 221. D ow nladed fom aimed to assess the association between depression and NAFLD. Methods A search of the literature was conducted on Medline and Embase databases to identify articles relating to NAFLD and depression. A meta-analysis of proportions was conducted using the generalized linear mix model with Copper Pearson intervals to stabilize the variance. Risk factors were analyzed using the odds ratios and mean difference for dichotomous and continuous variables respectively. To compare between the rate of depression between NAFLD (non-alcholic fatty liver disease) and NASH (nonalcoholic steatohepatitis), the relative risks (RR) were calculated using the depression in NASH vs NAFLD as the ratio of the pooled proportion and confidence interval by the Katz-logarithmic method. Results Of 1315 unique abstracts identified, 10 articles involving 2,041,752 NAFLD patients were included (IDDF2021ABS-0008 Figure 1. Overall Prevalence of Depression in NAFLD). In a pooled analysis of studies, there was a significant relationship between the diagnosis of depression and NAFLD (OR: 1.29, CI: 1.02 1.64, p=0.03). The overall pooled prevalence of depression in NAFLD was14.39% (CI: 8.89% 22.45%). The prevalence of depression in nonalcoholic steatohepatitis (NASH) is 40.68% (CI: 25.11% 58.37%), significantly higher than that in NAFLD at 14.39% (CI: 8.89% 22.45%). Compared to NAFLD, patients with NASH had a significantly higher risk of depression (RR: 2.83, CI: 2.41 3.32, p <0.001). Diabetes, BMI, female sex, history of smoking and history of lung disease were significant risk factors associated with depression in NAFLD patients and depression in NAFLD patients was an independent predictor of all-cause 1-year mortality. Conclusions To our knowledge, this is the first meta-analysis to describe a positive association between NAFLD and depression with an increasing rate of depression in NASH compared to NAFLD (IDDF2021-ABS-0008 Figure 2. Graphical Depiction of the Overall Results). However, more studies are required to observe the impact of depression and clinical outcomes in NAFLD. IDDF2021-ABS-0010 A META-ANALYSIS AND METAREGRESSION BETWEEN LIVER RESECTION AND LIVER TRANSPLANT WITHIN MILIAN CRITERIA Cheng Han Ng*, Jin Hean Koh, Yuki Ong, Wen Hui Lim, Darren Jun Hao Tan, Mark Muthiah, Nicholas Syn, Brian Goh, Daniel Huang. Yong Loo Lin School of Medicine, Singapore; Singapore General Hospital, Singapore 10.1136/gutjnl-2021-IDDF.62 Background Hepatocellular carcinoma (HCC) is the dominant form of primary liver cancer and a leading cause of cancer globally. Liver transplantation (LT) confers excellent long-term survival outcomes, but its effectiveness is hampered by the dire shortage of liver allografts. Liver resection (LR) is a promising alternative due to favorable","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89698910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDDF2021-ABS-0079 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: final 2-year efficacy and safety results from a phase 2 病毒性抑制的慢性乙型肝炎(CHB)肝功能损害患者从富马酸替诺福韦二氧丙酯(TDF)和/或其他口服抗病毒药物(OAVS)切换到替诺福韦alafenamide (TAF):来自2期的最终2年疗效和安全性结果
Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.81
Y. Lim, Chun‐Yen Lin, J. Heo, H. Bae, W. Chuang, T. Tsang, C. Fournier, A. Hui, H. Trinh, Carol Yee Kwan Chan, Susanna K. Tan, Yang Zhao, J. Flaherty, V. Suri, A. Gaggar, Dianna M Brainard, S. Ryder, H. Janssen
(HBV DNA
(HBV DNA
{"title":"IDDF2021-ABS-0079 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: final 2-year efficacy and safety results from a phase 2","authors":"Y. Lim, Chun‐Yen Lin, J. Heo, H. Bae, W. Chuang, T. Tsang, C. Fournier, A. Hui, H. Trinh, Carol Yee Kwan Chan, Susanna K. Tan, Yang Zhao, J. Flaherty, V. Suri, A. Gaggar, Dianna M Brainard, S. Ryder, H. Janssen","doi":"10.1136/gutjnl-2021-iddf.81","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.81","url":null,"abstract":"(HBV DNA <LLOQ x 6 months, <20 IU/mL at screening) with moderate or severe RI or with ESRD on HD at screening while receiving TDF and/or other OAVs for 48 weeks were enrolled and switched to TAF for 96 weeks. Safety assessments including adverse events (AEs), changes in bone BMD and renal (eGFRCG, serum phosphorus serum creatinine except in ESRD patients) parameters, viral suppression, serological and biochemical responses were serially assessed. Results Of 93 patients (mod-severe RI 78; ESRD on HD 15), most (74%) were male and Asian (77%), 51% 65 y, 83% HBeAg-negative, 34% cirrhosis, and median ALT 17 U/L. Up to 24% had osteoporosis at hip and/or spine, with most having comorbidities. Twelve (13%; 11 mod-severe RI and 1 ESRD) patients discontinued the study early (5-withdrew consent, 3-deaths [none treatment-related], 2-AE, 2investigator decision). Viral suppression (HBV DNA<20IU/ mL) was maintained in all patients remaining on treatment (i.e. missing equals excluded); a high proportion had target not detected. Overall, TAF was well tolerated with no Grade 3 ,4 or serious AEs related to study treatment. Relative to baseline levels, switching to TAF resulted in small median% increases in hip/spine BMD in those with moderate to severe RI, and small median decreases in ESRD patients. 2 patients with mod-severe RI had a bone fracture (ankle, rib). Median eGFRCG increased while urinary markers of proximal tubular function progressively decreased in mod-severe RI patients. Conclusions Renally-impaired CHB patients, including ESRD patients on HD, who were switched to TAF from TDF and/or other OAVs maintained high rates of viral suppression, and bone and renal parameters remained stable or slightly improved after 2 years of treatment.","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"71 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90877222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDDF2021-ABS-0159 The effect of curcumin supplement among overweight/obese non-alcoholic fatty liver disease (NAFLD) patients 姜黄素补充剂对超重/肥胖非酒精性脂肪性肝病(NAFLD)患者的影响
Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.98
Eduward Thendiono
{"title":"IDDF2021-ABS-0159 The effect of curcumin supplement among overweight/obese non-alcoholic fatty liver disease (NAFLD) patients","authors":"Eduward Thendiono","doi":"10.1136/gutjnl-2021-iddf.98","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.98","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82246883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDDF2021-ABS-0010 A meta-analysis and meta-regression between liver resection and liver transplant within milian criteria 肝切除和肝移植之间的meta分析和meta回归符合milian标准
Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.62
C. Ng, J. H. Koh, Y. Ong, W. Lim, Darren Jun Hao Tan, M. Muthiah, N. Syn, Brian Goh, Dan-chi Huang
{"title":"IDDF2021-ABS-0010 A meta-analysis and meta-regression between liver resection and liver transplant within milian criteria","authors":"C. Ng, J. H. Koh, Y. Ong, W. Lim, Darren Jun Hao Tan, M. Muthiah, N. Syn, Brian Goh, Dan-chi Huang","doi":"10.1136/gutjnl-2021-iddf.62","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.62","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83530539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDDF2021-ABS-0019 An epidemiological meta-analysis on the worldwide prevalence, resistance and outcomes of spontaneous bacterial peritonitis in cirrhosis 肝硬化自发性细菌性腹膜炎的全球患病率、耐药性和结局的流行病学荟萃分析
Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.64
C. Ng, Phoebe Wen Lin Tay, J. Xiao, Darren Jun Hao Tan, Yan Nerng Lye, W. Lim, Vanessa Xin Yi Teo, Ryan Rui Yang Heng, Marcus Wei Xuan Yeow, Lionel Hon Wai Lum, Eunice Xiang Xuan Tan, G. S. Kew, G. Lee, M. Muthiah
{"title":"IDDF2021-ABS-0019 An epidemiological meta-analysis on the worldwide prevalence, resistance and outcomes of spontaneous bacterial peritonitis in cirrhosis","authors":"C. Ng, Phoebe Wen Lin Tay, J. Xiao, Darren Jun Hao Tan, Yan Nerng Lye, W. Lim, Vanessa Xin Yi Teo, Ryan Rui Yang Heng, Marcus Wei Xuan Yeow, Lionel Hon Wai Lum, Eunice Xiang Xuan Tan, G. S. Kew, G. Lee, M. Muthiah","doi":"10.1136/gutjnl-2021-iddf.64","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.64","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"62 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87157004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDDF2021-ABS-0084 Tuberculosis as a common cause of post-liver transplant ascites 结核病是肝移植后腹水的常见原因
Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.84
T. Sowmya
Background To assess the quality of life (QoL) of patients with hepatocellular carcinoma (HCC) by the European Organi-zation for the Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ- C30). Methods A prospective study was conducted from August 2020 to August 2021. We evaluated the QoL of 30 patients diagnosed of HCC at Bach Mai and Hanoi Medical University Hospital after a month of treatment. EORTC-QLQ C30 items were converted to scores according to an available formula, the total score for each section ranged from 0 to 100. A low functional score reflected a low QoL, while a lower symptom score indicated a higher QoL. The overall EORTC score (C30 index score) would be calculated according to the available formula. The lower the C30 index score was, the better the QoL would be. and
背景采用欧洲癌症研究与治疗组织生活质量问卷(EORTC QLQ- C30)评估肝细胞癌(HCC)患者的生活质量(QoL)。方法于2020年8月至2021年8月进行前瞻性研究。我们评估了在巴赫迈和河内医科大学医院治疗一个月后诊断为HCC的30例患者的生活质量。EORTC-QLQ C30项根据可用的公式转换为分数,各部分的总分范围为0 - 100。功能评分越低,生活质量越低,症状评分越低,生活质量越高。EORTC总得分(C30指数得分)将根据可用的公式计算。C30指数得分越低,生活质量越好。和
{"title":"IDDF2021-ABS-0084 Tuberculosis as a common cause of post-liver transplant ascites","authors":"T. Sowmya","doi":"10.1136/gutjnl-2021-iddf.84","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.84","url":null,"abstract":"Background To assess the quality of life (QoL) of patients with hepatocellular carcinoma (HCC) by the European Organi-zation for the Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ- C30). Methods A prospective study was conducted from August 2020 to August 2021. We evaluated the QoL of 30 patients diagnosed of HCC at Bach Mai and Hanoi Medical University Hospital after a month of treatment. EORTC-QLQ C30 items were converted to scores according to an available formula, the total score for each section ranged from 0 to 100. A low functional score reflected a low QoL, while a lower symptom score indicated a higher QoL. The overall EORTC score (C30 index score) would be calculated according to the available formula. The lower the C30 index score was, the better the QoL would be. and","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73377122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
IDDF2021-ABS-0070 Predictive performance of the hap score at patients with hepatocellular carcinoma following trans-arterial chemoembolisation (TACE) 肝细胞癌经动脉化疗栓塞(TACE)后hap评分的预测性能
Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.77
Anh Tran Ngoc, H. Trung, Lieu Dau Quang
{"title":"IDDF2021-ABS-0070 Predictive performance of the hap score at patients with hepatocellular carcinoma following trans-arterial chemoembolisation (TACE)","authors":"Anh Tran Ngoc, H. Trung, Lieu Dau Quang","doi":"10.1136/gutjnl-2021-iddf.77","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.77","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"150 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79082647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDDF2021-ABS-0040 Less liver fibrosis marker increment in overweight chronic hepatitis b patients observed by age-adjusted fibrosis-4 index 年龄调整纤维化-4指数观察超重慢性乙型肝炎患者肝纤维化标志物增加较少
Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.68
Tasia Liu
{"title":"IDDF2021-ABS-0040 Less liver fibrosis marker increment in overweight chronic hepatitis b patients observed by age-adjusted fibrosis-4 index","authors":"Tasia Liu","doi":"10.1136/gutjnl-2021-iddf.68","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.68","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74771880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDDF2021-ABS-0184 Global incidence and risk factors of pancreatic cancer among young adults: an epidemiological study 年轻人胰腺癌的全球发病率和危险因素:一项流行病学研究
Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.101
Junjie Huang, Alfonse Ngai, Veeleah Lok, Xianjing Liu, Lin Zhang, Jinqiu Yuan, Wanghong Xu, Zhi‐Jie Zheng, Martin C. S. Wong
IDDF2021-ABS-0184 Figure 1 Global incidence of youngonset pancreatic cancer in 2020 Abstracts Gut 2021;70(Suppl 2):A1–A150 A91 on S etem er 5, 2021 by gest. P rocted by coright. http/gut.bm jcom / G t: frst pulished as 10.113utjnl-2021-ID D F .02 on 2 S etem er 221. D ow nladed fom Methods A cross-sectional study of all eligible LT recipients from 2008 to 2020 in a leading transplant centre in Singapore was conducted to determine the vaccine response in HBV-naïve subjects. A standardised workflow was devised to identify barriers in vaccination and response monitoring. Transplant coordinators and pharmacists assisted physicians to identify and prescribe CDC-recommended vaccinations using a template, which include Engerix 40mcg of three doses, followed by rechecking anti-HBs titre one month after. A second 3-dose Engerix regimen was given if anti-HBs remains <10 mIU/mL. Non-responder is defined as failure to achieve protective anti-HBs titre after completing two cycles. Results Of the 279 LT recipients, we excluded patients not on follow-up and patients with anti-HBc positivity. 75 patients were included. Prior to vaccination implementation, 9/75 (12%) were not checked for anti-HBs. Of the 66 checked, 40 required vaccination. 29/40 (72.5%) were started on the first cycle, and 21/40 (52.5%) completed. 11/20 (55%) patients were initiated on the second cycle. Post workflow implementation, 40 needed vaccination. 34/40 (85%) were started on the first cycle and 24/40 (60%) completed. 18/23 (78.3%) were started on a second cycle. 3/4 (75%) were non-responders (IDDF2021-ABS-0190 Figure 1). Our implementation coincided with the COVID-19 pandemic where more teleconsultation was used. COVID-19 vaccination was also prioritised over HBV vaccination. We postulate that these results would be further improved once physical consultations resumed. Conclusions The development of a standardised workflow can lead to improvement in anti-HBs testing and compliance to vaccination post-LT. These findings may be useful for other patients who are on long-term immunosuppression. Continual efforts from the multidisciplinary team are required to ensure the sustainability of effect. IDDF2021-ABS-0203 A SCREENING MODEL FOR OBSTRUCTIVE SLEEP APNEA ON THE BASIS OF FATTY LIVER DISEASE-RELATED PARAMETERS Yang-Bor Lu*, Yu-Chieh Weng, Yung-Ning Huang, Hsiung-Ying Huang, PeiTing Cheng, Hui-Shan Hsieh, Ming-Shao Tsai. Department of Digestive Disease, Xiamen Chang Gung Hospital, Xiamen, China; Hepatobiliary and Pancreatic Unit, Xiamen Chang Gung Hospital, Xiamen, China; Department of Pulmonary and Critical Care Medicine, Sleep center, Xiamen Chang Gung Hospital, Xiamen, China; Formosa Biomedical Technology Corp., Taipei, Taiwan; Department of Otolaryngology-Head and Neck Surgery, Sleep center, Xiamen Chang Gung Hospital, Xiamen, China; Department of Otolaryngology-Head and Neck Surgery, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan; College of Medicine, Chang Gung University, Taoyua
图1 2020年全球年轻组胰腺癌发病率[摘要]Gut 2021;70(补充2):A1-A150 A91,截止到2021年5月5日。P由赖特保护。http /直觉。[j] [j]:首次发表于10.113utjnl-2021-ID D F .02年2月1日,第221页。研究人员对新加坡一家主要移植中心2008年至2020年所有符合条件的肝移植受者进行了一项横断面研究,以确定HBV-naïve受试者的疫苗应答。制定了标准化工作流程,以确定疫苗接种和应对监测方面的障碍。移植协调员和药剂师协助医生使用模板确定和开出cdc推荐的疫苗,其中包括三剂Engerix 40mcg,然后在一个月后重新检查抗hbs滴度。如果抗hbs为24.8,优势比为1.42 [95% CI: 1.091.86]), HSI(> 38.3,优势比为1.17 [95% CI: 1.021.36])显著筛查OSA风险,则给予第二组3剂Engerix方案。多因素分析显示,男性性别、BMI和HSI独立筛查OSA,其联合筛查OSA风险最佳(敏感性= 78%;特异性= 85%;阳性预测值为95%,阴性预测值为52%;曲线下面积= 0.85)。我们的研究结果表明,HSI比CAP具有更好的筛查效果。本文提出的男性、BMI和HSI的结合为OSA风险提供了一种无创、快速的筛查工具。该模型可用于临床患者的肝脏常规检查。这可用于有效筛查高危患者,从而促进早期发现和及时治疗干预。临床胃肠病学IDDF2021-ABS-0005肠衰竭患者肠外营养支持团队:改善宏量及微量营养素的摄入何燕丁兆霆*,洪凯,陆兆文,史培,吕丽娟,闫晓燕,陈雪莲,金浩,麦兆文,洪凯,梁奕德,林玉英,王志仁,尹伟,陆淑丽香港医院管理局北区医院营养支援组10.1136/gutjnl-2021-IDDF.104营养支持小组(NST)是一个由医生、药剂师、护士和营养师组成的多学科团队,负责管理具有复杂营养需求的患者。NST通过避免不必要的治疗和简化所使用的治疗,提高了治疗质量和临床结果,并降低了成本。本研究回顾了一组在当地急症医院给予肠外营养(PN)的患者实施NST后取得的结果。方法检索81例患者病历,进行服务评价分析。在受试者中,2017年4月至2019年6月在NST就诊的44例PN患者与37例历史对照进行比较。P由赖特保护。http /直觉。[j] [j]:首次发表于10.113utjnl-2021-ID D F .02年2月1日,第221页。我们从
{"title":"IDDF2021-ABS-0184 Global incidence and risk factors of pancreatic cancer among young adults: an epidemiological study","authors":"Junjie Huang, Alfonse Ngai, Veeleah Lok, Xianjing Liu, Lin Zhang, Jinqiu Yuan, Wanghong Xu, Zhi‐Jie Zheng, Martin C. S. Wong","doi":"10.1136/gutjnl-2021-iddf.101","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.101","url":null,"abstract":"IDDF2021-ABS-0184 Figure 1 Global incidence of youngonset pancreatic cancer in 2020 Abstracts Gut 2021;70(Suppl 2):A1–A150 A91 on S etem er 5, 2021 by gest. P rocted by coright. http/gut.bm jcom / G t: frst pulished as 10.113utjnl-2021-ID D F .02 on 2 S etem er 221. D ow nladed fom Methods A cross-sectional study of all eligible LT recipients from 2008 to 2020 in a leading transplant centre in Singapore was conducted to determine the vaccine response in HBV-naïve subjects. A standardised workflow was devised to identify barriers in vaccination and response monitoring. Transplant coordinators and pharmacists assisted physicians to identify and prescribe CDC-recommended vaccinations using a template, which include Engerix 40mcg of three doses, followed by rechecking anti-HBs titre one month after. A second 3-dose Engerix regimen was given if anti-HBs remains <10 mIU/mL. Non-responder is defined as failure to achieve protective anti-HBs titre after completing two cycles. Results Of the 279 LT recipients, we excluded patients not on follow-up and patients with anti-HBc positivity. 75 patients were included. Prior to vaccination implementation, 9/75 (12%) were not checked for anti-HBs. Of the 66 checked, 40 required vaccination. 29/40 (72.5%) were started on the first cycle, and 21/40 (52.5%) completed. 11/20 (55%) patients were initiated on the second cycle. Post workflow implementation, 40 needed vaccination. 34/40 (85%) were started on the first cycle and 24/40 (60%) completed. 18/23 (78.3%) were started on a second cycle. 3/4 (75%) were non-responders (IDDF2021-ABS-0190 Figure 1). Our implementation coincided with the COVID-19 pandemic where more teleconsultation was used. COVID-19 vaccination was also prioritised over HBV vaccination. We postulate that these results would be further improved once physical consultations resumed. Conclusions The development of a standardised workflow can lead to improvement in anti-HBs testing and compliance to vaccination post-LT. These findings may be useful for other patients who are on long-term immunosuppression. Continual efforts from the multidisciplinary team are required to ensure the sustainability of effect. IDDF2021-ABS-0203 A SCREENING MODEL FOR OBSTRUCTIVE SLEEP APNEA ON THE BASIS OF FATTY LIVER DISEASE-RELATED PARAMETERS Yang-Bor Lu*, Yu-Chieh Weng, Yung-Ning Huang, Hsiung-Ying Huang, PeiTing Cheng, Hui-Shan Hsieh, Ming-Shao Tsai. Department of Digestive Disease, Xiamen Chang Gung Hospital, Xiamen, China; Hepatobiliary and Pancreatic Unit, Xiamen Chang Gung Hospital, Xiamen, China; Department of Pulmonary and Critical Care Medicine, Sleep center, Xiamen Chang Gung Hospital, Xiamen, China; Formosa Biomedical Technology Corp., Taipei, Taiwan; Department of Otolaryngology-Head and Neck Surgery, Sleep center, Xiamen Chang Gung Hospital, Xiamen, China; Department of Otolaryngology-Head and Neck Surgery, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan; College of Medicine, Chang Gung University, Taoyua","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84852702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDDF2021-ABS-0102 Retrospective analysis of characteristics, indications and outcomes of ercp in a tertiary referral center of Saudi Arabia 沙特阿拉伯某三级转诊中心ercp的特点、适应证和转归回顾性分析
Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.90
Laeeque Ahmed, Ahmed Basalim, N. Alwagdani, Bsaim Altirkistani, Ziyad M. Albassam, Mohammed A Almatrafi, Faisal S Alrubaei, Adnan Alzanbagi
IDDF2021-ABS-0116 Figure 2 Abstract IDDF2021-ABS-0116 Figure 3 AbstractsIDDF2021-ABS-0116 Figure 3 Abstracts Gut 2021;70(Suppl 2):A1–A150 A85 on S etem er 5, 2021 by gest. P rocted by coright. http/gut.bm jcom / G t: frst pulished as 10.113utjnl-2021-ID D F 92 on 2 S etem er 221. D ow nladed fom 32 studies described tumors with a specified primary, with gastric cancer being the most common. (IDDF2021-ABS-0116 Figure 1) Pooled data showed that the 3and 5-year OS were 45% (95% CI 0.40-0.50) and 35% (95% CI 0.31-0.19), (IDDF2021-ABS-0116 Figure 2, IDDF2021-ABS-0116 Figure 3) respectively, whereas the 3and 5-year DFS were 33% (95% CI 0.29-20.37) and 27% (95% CI 0.23-0.32), respectively (IDDF2021-ABS-0116 Figure 4, IDDF2021-ABS-0116 Figure 5). The postoperative morbidity rate was 24% (95% CI 0.20-0.29), whereas the 30-day mortality was 2% (95% CI 0.01-0.03). Gastric cancer with liver metastasis had 3-year and 5-year OS of 39% (95% CI 0.32-0.46) and 25% (95% CI 0.20-0.31). Conclusions Hepatectomy for NCNNLM may achieve favourable survival outcomes, with low surgical morbidities and mortalities in selected patients. IDDF2021-ABS-0118 FACTORS ASSOCIATED WITH THE PRESENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DETECTED IN JAPANESE ADULTS UNDERGOING HEALTH
IDDF2021-ABS-0116图2摘要IDDF2021-ABS-0116图3摘要siddf2021 - abs -0116 Gut 2021;70(补充2):A1-A150 A85在S etem er 5上,2021按最大。P由赖特保护。http /直觉。jj.com / gt:首次发表于10.113utjnl-2021-ID D F 92年2月1日,第221页。32项研究中有1项描述了具有特定原发灶的肿瘤,其中以胃癌最为常见。(IDDF2021-ABS-0116图1)汇总数据显示,3年和5年OS分别为45% (95% CI 0.40-0.50)和35% (95% CI 0.31-0.19) (IDDF2021-ABS-0116图2,IDDF2021-ABS-0116图3),而3年和5年DFS分别为33% (95% CI 0.29-20.37)和27% (95% CI 0.23-0.32) (IDDF2021-ABS-0116图4,IDDF2021-ABS-0116图5)。术后发病率为24% (95% CI 0.20-0.29), 30天死亡率为2% (95% CI 0.01-0.03)。胃癌合并肝转移的3年和5年OS分别为39% (95% CI 0.32-0.46)和25% (95% CI 0.20-0.31)。结论肝切除术治疗NCNNLM可能获得良好的生存结果,在选定的患者中手术发病率和死亡率较低。Iddf2021-abs-0118与日本健康成人非酒精性脂肪性肝病(nafld)存在相关的因素
{"title":"IDDF2021-ABS-0102 Retrospective analysis of characteristics, indications and outcomes of ercp in a tertiary referral center of Saudi Arabia","authors":"Laeeque Ahmed, Ahmed Basalim, N. Alwagdani, Bsaim Altirkistani, Ziyad M. Albassam, Mohammed A Almatrafi, Faisal S Alrubaei, Adnan Alzanbagi","doi":"10.1136/gutjnl-2021-iddf.90","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.90","url":null,"abstract":"IDDF2021-ABS-0116 Figure 2 Abstract IDDF2021-ABS-0116 Figure 3 AbstractsIDDF2021-ABS-0116 Figure 3 Abstracts Gut 2021;70(Suppl 2):A1–A150 A85 on S etem er 5, 2021 by gest. P rocted by coright. http/gut.bm jcom / G t: frst pulished as 10.113utjnl-2021-ID D F 92 on 2 S etem er 221. D ow nladed fom 32 studies described tumors with a specified primary, with gastric cancer being the most common. (IDDF2021-ABS-0116 Figure 1) Pooled data showed that the 3and 5-year OS were 45% (95% CI 0.40-0.50) and 35% (95% CI 0.31-0.19), (IDDF2021-ABS-0116 Figure 2, IDDF2021-ABS-0116 Figure 3) respectively, whereas the 3and 5-year DFS were 33% (95% CI 0.29-20.37) and 27% (95% CI 0.23-0.32), respectively (IDDF2021-ABS-0116 Figure 4, IDDF2021-ABS-0116 Figure 5). The postoperative morbidity rate was 24% (95% CI 0.20-0.29), whereas the 30-day mortality was 2% (95% CI 0.01-0.03). Gastric cancer with liver metastasis had 3-year and 5-year OS of 39% (95% CI 0.32-0.46) and 25% (95% CI 0.20-0.31). Conclusions Hepatectomy for NCNNLM may achieve favourable survival outcomes, with low surgical morbidities and mortalities in selected patients. IDDF2021-ABS-0118 FACTORS ASSOCIATED WITH THE PRESENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DETECTED IN JAPANESE ADULTS UNDERGOING HEALTH","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"66 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91511588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Chinese Journal of Clinical Hepatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1